ABVC BioPharma receives Taiwanese patent for MDD treatment

ABVC BioPharma received a Taiwanese patent, Application No. 109130285, for the use of PDC-1421, a Radix Polygala extract, which is used in the Company’s asset ABV-1504 for the treatment of Major Depressive Disorder. The Company was previously awarded a U.S. patent, US 11,554,154 B2, on April 25, 2023, for the same treatment. The patent application was submitted to the Taiwan Patent and Trademark Office under the title “Polygala Extract for the Treatment of Major Depressive Disorder.” The invention relates to oral administration of the formulation containing a Radix Polygala extract, PDC-1421, as a capsule for treating Major Depressive Disorder. Based on current studies, administering the composition should be done over the course of at least 25 days, with the daily dose varying once, twice, or three times per day; each dose ranges between 380-760 mg of the botanical extraction. ABV-1504, the Company’s asset indicated for use in MDD containing PDC-1421, is a botanical-based Norepinephrine Transporter inhibitor that has completed Phase II clinical studies, with plans to initiate an End of Phase II meeting with the FDA.